The evolving landscape of pulmonary arterial hypertension clinical trials-Reference-Cited by-同舟云学术

The evolving landscape of pulmonary arterial hypertension clinical trials

Published:2022-11 Issue:10366 Volume:400 Page:1884-1898
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Weatherald Jason,Boucly Athénaïs,Peters Anthony,Montani David,Prasad Krishna,Psotka Mitchell A,Zannad Faiez,Gomberg-Maitland Mardi,McLaughlin Vallerie,Simonneau Gérald,Humbert Marc

Publisher

Elsevier BV

Subject

General Medicine

Reference133 articles.

1. Pulmonary arterial hypertension;Hassoun;N Engl J Med,2021

2. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era;Zelt;Eur Respir J,2022

3. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry;Hoeper;Eur Respir J,2022

4. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry;Boucly;Eur Respir J,2022

5. Clinical trial design and new therapies for pulmonary arterial hypertension;Sitbon;Eur Respir J,2019

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting;Respiratory Medicine and Research;2024-11

2. Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension;CHEST;2024-09

3. Exploring the patient perspective in pulmonary hypertension;European Respiratory Journal;2024-08-29

4. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension;European Respiratory Journal;2024-08-29